Arix Bioscience PLC (LON:ARIX)

Arix Bioscience PLC (LON:ARIX)

Share Price
141.50 p
0 (0.00 %)
Market Cap
£190.94 m
Proactive Investors - Run By Investors For Investors

Arix Bioscience PLC

Arix Bioscience is a global healthcare and life science company that drives value in private and public companies through operational and strategic direction as well as patient capital.

Led by renowned figures in the healthcare and life science sectors, Arix Bioscience is headquartered in London and has an office in New York.

Our extensive experience in academic science, clinical...

Market: LSE:ARIX
52-week High/Low: 213.00p / 138.00p
Sector: Health Care, Equipment & Services
Market Cap: £190.94 m
col 3
col 4
col 5
col 6

Joe Anderson, chief executive of Arix Biosciences PLC (LON:ARX), pitches the company to investors. For more information visit

Big Picture – A Deep Dive Examination of Arix Bioscience PLC

Arix Bioscience PLC Snapshot

Arix Bioscience sources, finances and develops both start-up and later-stage companies across healthcare and life science sectors globally.
We relentlessly seek out the best innovative science to build our international group of healthcare and life science businesses.

We recognise the values of rigorous due diligence patient investing and strategic guidance.

We are confident that our extensive management experience will ensure these companies flourish, maximising value for investors.

Dr Joe Anderson
Chief Executive Officer

Joe has over 25 years’ experience in the life sciences industry with a successful track record of generating investment returns. He was a partner at Abingworth LLP for 12 years, where he led venture-capital style investments in public companies. He has founded and managed public equities funds and been a director of Algeta (acquired by Bayer AG for $2.9 billion), Amarin plc, Cytos (merged with Kuros) and Epigenomics AG, and is currently a director of Autolus Ltd.

Joe began his career at the Ciba (now Novartis) Foundation, before joining The Wellcome Trust in 1990 where he became head of the strategy team. He then moved to the City of London as a pharmaceuticals analyst at Dresdner Kleinwort Benson before being appointed as Head of Global Healthcare and Portfolio Manager at First State Investments, Commonwealth Bank of Australia, in London. Joe has a PhD in Biochemistry and extensive board level experience of building successful life science companies.


Jonathan Peacock

Jonathan has 35 years’ global experience in operations, strategy and business development and extensive expertise within the Biopharma industry. Jonathan is the former CFO of Amgen Inc based in California, USA and prior to that was the CFO of the Pharmaceuticals Division of Novartis AG, based in Switzerland. During Jonathan’s tenure as CFO at Amgen Inc the stock price increased by approximately 125% and at Novartis operating profits increased by over 40%. He has raised over $20 billion in new capital and throughout his career has been engaged in business development and mergers and acquisitions on both the buy-side and sell-side, globally.

Before joining the pharmaceutical industry, Jonathan was a partner at McKinsey & Company where he was co-head of the European Corporate Finance practice. Jonathan was also a partner at PricewaterhouseCoopers in London and New York. Jonathan is currently Chairman of Bellerophon Therapeutics and is a non-executive director of Kite Pharma, both of which are listed on NASDAQ. He has a Masters degree in Economics from the University of St Andrews in Scotland.


Sir Chris Evans
Deputy Chairman

Sir Chris is a renowned scientist and highly successful entrepreneur with numerous prestigious awards and medals for his work over the last 30 years. He is the founder and Chairman of Excalibur Group and has created 11 successful academic spin-outs and founded notable companies such as Chiroscience, Celsis, BioVex, ReNeuron, Vectura and Merlin Biosciences Ltd. He directed the raising of approximately $450 million for Merlin Biosciences Funds and $2.6 billion from disposals including the sale of BioVex Group, Inc to Amgen Inc and Piramed Limited to Roche Group.

Through Merlin Ventures Limited, he co-founded and advised Biotech Growth Trust plc and Arakis Limited, one of the companies developed by Sir Chris which was sold to Sosei Co. Ltd for $187 million. Sir Chris has founded multiple listed companies with a collective market cap (as at the end of April 2016) of around $2.4 billion. Appointed OBE in 1995 for services to medical bioscience, he was then knighted in 2001 for services to bioscience and enterprise.


James Rawlingson
Chief Financial Officer

James has substantial experience at board and senior management level gained over 20 years of involvement in financial services and UK public companies. James’ former role was Group CFO of Charles Stanley plc, a leading wealth manager with over £20 billion of funds under management and administration. Previously, James was Group CFO for Coutts Bank, where he was responsible for the global finance function and held a key role in setting strategy. Before this James spent two years at UBS Wealth Management based in Zurich after promotion from his role as CFO of UBS Wealth UK.


Franz Humer
Senior Non-Executive Director

Franz has over 25 years’ extensive experience in acting as an executive director of global blue chip companies. In 1995, he joined Hoffmann-La Roche’s board, then progressing to become CEO and Chairman at Roche Holding Ltd over a period of 16 years. Previous to this he held various global and pivotal roles at Glaxo Pharmaceuticals and Glaxo Holdings, including a seat on the board.

Franz joined the board of Diageo in 2005 and became chairman in 2008. He is also a non-executive director of Citigroup, Inc, Chugai Pharmaceuticals Limited of Japan, Bial Pharmaceuticals of Portugal, Kite Pharma and WISeKey of Switzerland and a member of the international advisory board of Allianz SE. Franz has a PhD in law from the University of Innsbruck and an MBA from INSEAD in Fontainebleau. He is the Chairman of the board of directors of the International Centre for Missing and Exploited Children. Franz has been awarded the Singapore Public Service Star and the “Grosses goldenes Ehrenzeichen mit dem Stern für Verdienste” of Austria.


Professor Trevor Jones
Independent Non-Executive Director

Trevor has led a distinguished career in the pharmaceutical and biotech industry as well as in academia. He was Group R&D director at The Wellcome Foundation, responsible for the development of AZT, Zovirax, Lamictal, Malarone and other medicines. Following this, he was a director of Allergan Inc (USA) for 10 years until 2015. Trevor was formerly Director General of the Association of the British Pharmaceutical Industry (ABPI), served for 12 years as a member of the UK Government Regulatory Agency Medicines Commission and acted as chairman of the UK Government Advisory Group on Genetics Research. He is a visiting professor at King’s College, London and holds honorary degrees and gold medals from six universities. In 2004, he was appointed to the World Health Organisation Commission on Intellectual Property Rights, Innovation and Public Health. In 2003, Trevor was appointed CBE for services to the pharmaceutical industry.


David U’Prichard
Independent Non-Executive Director

David trained as a pharmacologist in Scotland. During a 45-year career in the USA, David has been a leader in drug receptor research, pharmaceutical R&D, biotechnology and venture investing.  With an academic career at the Johns Hopkins University and Northwestern University medical schools, David then led Zeneca’s global research activities, and subsequently, Smith Kline Beecham’s R&D in the 1990s. David led 3-Dimensional Pharmaceuticals, Inc. to an IPO in 2000 and then a sale to Johnson & Johnson in 2003.  He is an experienced early stage venture capitalist and corporate director in both the USA and the UK.  From 2012 David has worked to establish The Harrington Project, a USA-wide non-profit scholarship scheme to translate the best American academic research towards new drug development and is a member of the Board of managers of BioMotiv, and the chairman of the Scientific Advisory Board of BioMotiv.


Giles Kerr
Independent Non-Executive Director

Giles has 36 years’ experience in finance across a broad range of industrial sectors with a particular focus on life sciences. He is currently CFO of Oxford University and during his time at Oxford has established a successful investment office with £2.5bn under management and a £650m early-stage investment fund. Through his role on the board of Oxford University’s technology transfer company, Oxford University Innovation Ltd., he has gained considerable experience of establishing and growing technology based companies. Prior to joining Oxford University he was CFO of Amersham plc and during his time at Amersham the share price increased seven fold. Giles has extensive experience as chairman and as a member of UK and US listed company audit committees and is currently Chairman of the audit committees of Senior plc, Paypoint plc and a member of the audit committees of BTG plc and Adaptimune Therapeutics plc. Prior to joining Amersham plc he was an audit partner with Arthur Anderson & Co.


Meghan FitzGerald
Independent Non-Executive Director

Meghan has broad experience in the US healthcare industry, with a strong emphasis on operations, health policy and business development. She is a Partner at L1 Health, with a focus on investing in healthcare services. She is also an Associate Professor of Strategy and Health Policy at Columbia University. Prior to joining L1 Health, Meghan served as Executive Vice President of Strategy and Health Policy at Cardinal Health, the global integrated healthcare services and products provider, and before then was President of Cardinal’s Specialty Solutions division. She holds a DrPh in Healthcare Policy from New York Medical College, a BSN in Nursing from Fairfield University, and a Master of Public Health from Columbia University.


Business Development Team

Edward Rayner

Before joining Arix Bioscience at its inception, Ed spent 18 years as an equity analyst and Portfolio Manager in Europe and Australia. From 2004 to 2014, he was Head of Research at Alliance Bernstein and then a senior portfolio manager at AMP Capital, a leading Australian investment house with over A$130bn in funds under management, both in Sydney, Australia. At AMP Capital, he managed the growth equity portfolios and launched a small companies fund. As part of his responsibilities he focused on the Healthcare sector.

Prior to his move to Australia, Ed analysed European equities at UBS Asset Management and JP Morgan Investment Management. He gained an MA in Chemistry and MSc in Management at the University of Oxford and is a Chartered Financial Analyst.


Jonathan Tobin

Jonathan specialises in biotechnology investments. He currently sits on the board of Artios Pharma. Prior to joining Arix Bioscience, Jonathan spent five years at Imperial Innovations, where he was a Principal in the Healthcare Ventures team. He was involved with the formation and investment in a number of early stage companies, including Inivata, Auspherix, Abingdon Health, Cell Medica, and Psioxus. Jonathan also worked at MRC Technology, sourcing and evaluating new small molecule and antibody drug discovery projects.

He has a first class degree in biology from the University of Oxford, a PhD in Molecular Medicine from UCL, carried out postdoctoral research at the Cancer Research UK London Research Institute (now Crick Institute), and published research in journals including PNAS, New England Journal of Medicine, and Nature Genetics. Jonathan also has an MBA with distinction from Imperial College, and is a Trustee of the Autism Research Trust.


Mark Chin

Mark has over 10 years’ of experience in the life sciences industry.  He was previously a principal at Longitude Capital, where he focused on investments in both private and public biotechnology and medical technology companies.  Prior to Longitude, he was a consultant at the Boston Consulting Group, where he was responsible for strategy and corporate development projects for pharmaceutical and biotechnology companies.  Before BCG, Mark worked in corporate development at Gilead Sciences and market planning at Genentech.  Mark has an MBA from The Wharton School at the University of Pennsylvania, an MS in Biotechnology from the University of Pennsylvania, and a BS in Management Science from the University of California at San Diego.


Daniel O’Connell

Daniel has over 10 years’ of experience in healthcare. Daniel joined Arix Bioscience from OrbiMed Advisors, where he played key roles across investments in both biotherapeutics and medical devices. Investments he has supported include CardiAQ (acquired by Edwards), Civitas Therapeutics (acquired by Acorda), Relypsa (acquired by Galenica), Cynapsus (acquired by Sunovion), as well as other public and private companies.  Prior to OrbiMed, Daniel was the Associate Director of Cardiovascular Research at Arisaph Pharmaceuticals where he was responsible for pre-IND discovery and development for programs in lipid modulation. He received his MD and PhD in Biochemistry from Tufts University School of Medicine, and has undergraduate degrees in Mathematics and Chemistry from MIT.

Arix Bioscience
20 Berkeley Square

+44 (0)20 7290 1050
[email protected]


50 West 55th Street
33rd Floor
New York NY 10019

+1 (646) 357 3700
[email protected]

Columns Including ARIX


Market Reports Including ARIX

Video RSS



© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use